{"id":"fentanyl-taifun","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL1201159","moleculeType":"Small molecule","molecularWeight":"372.94"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fentanyl acts as a mu-opioid receptor agonist, activating inhibitory pathways in the spinal cord and brain that reduce pain signal transmission and perception. The TAIFUN formulation appears to be a delivery system variant designed to optimize pharmacokinetics and patient tolerability. By modulating opioid receptor signaling, fentanyl produces dose-dependent analgesia, sedation, and respiratory depression.","oneSentence":"Fentanyl TAIFUN is a transdermal or inhalation formulation of fentanyl, a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:21.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain (specific indication pending phase 3 results)"}]},"trialDetails":[{"nctId":"NCT00822614","phase":"PHASE3","title":"Safety of Fentanyl TAIFUN Treatment","status":"UNKNOWN","sponsor":"Akela Pharma, Inc.","startDate":"2008-12","conditions":"Breakthrough Cancer Pain","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fentanyl TAIFUN","genericName":"Fentanyl TAIFUN","companyName":"Akela Pharma, Inc.","companyId":"akela-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fentanyl TAIFUN is a transdermal or inhalation formulation of fentanyl, a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Moderate to severe pain (specific indication pending phase 3 results).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}